Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2014. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility regarding their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary Shares by various directors and executives on April 10, 2014. These acquisitions resulted from the reinvestment of dividends paid on shares held in the GlaxoSmithKline ShareReward Plan. The purchase price was 1585.037 pence per Ordinary Share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of specific share purchases under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: April 10, 2014.
- Share Price: 1585.037 pence per Ordinary Share.
- Transaction Type: Dividend reinvestment via the ShareReward Plan.
- Participants: Sir Andrew Witty, Mr S Dingemans, Mr S M Bicknell, Mr R G Connor, Mr S A Hussain, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.
- Notification Date: April 11, 2014.